Advances in cutaneous lymphoma treatment;Postȩpy w leczeniu chłoniaków skóry

Przeglad Dermatologiczny

Volumn 93, Issue 2, 2006, Pages 153-159

  Placek, W ^a   Grzanka, A ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; DENILEUKIN DIFTITOX; IMIQUIMOD; MONOCLONAL ANTIBODY; RETINOID; VACCINE;

B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SUBPOPULATION; CELL TYPE; CONFERENCE PAPER; CONTROLLED STUDY; EXCIMER LASER; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PALLIATIVE THERAPY; PHOTODYNAMICS; PHOTOTHERAPY; PUVA; SKIN LYMPHOMA; SKIN TUMOR; SYSTEMIC THERAPY; T CELL LYMPHOMA; T LYMPHOCYTE; ULTRAVIOLET B RADIATION;

EID: 33744494002     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998;134:949-54.
2. Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987;5:1796-1803.
3. Vonderheid EC, Tan ET, Kantor AF I inni. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine hemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20:416-428.
4. Zackheim HS, Epstein EH, Jr., Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 990;22(5 Pt 1):802-810.
5. Breneman D, Duvic M, Kuzel T, i inni. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32.
6. Sidky Y.A., Borden B.C., Weeks C.E I inni. Inhibition of nurine tumor growth by an interferon inducing imidazolquimodi namine. Cancer Res., 1992, 52, 3528-3533.
7. Deeths MJ, Chapman JT, Dellavalle RP I inni. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275-80.
8. Didona B, Benucci R, Amerio P i inni. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol. 2004, 150(6):1198-201.
9. Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. J Am Acad Dermatol 1993;29:73-7.
10. Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992;128:931-933.
11. Gathers RC, Scherschun L, Malick F i inni. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 2002;47:191-7.
12. Coven TR, Burack LH, Gilleaudeau R i inni. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 1997;133:1514-22.
13. Herrmann JJ, Roenigk HH, Jr, Hurria A, i inni. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995;33:234-42.
14. Gilchrest BA, Parrish JA, Tanenbaum L, i inni. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976;38:683-9.
15. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998;90:1278-84.
16. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997;336:1041-5.
17. Orenstein A, Haik J, Tamir J i inni. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg. 2000 Aug;26(8):765-9; discussion 769-70.
18. Mori M, Campolmi P, Mavilia L I inni. Topical photodynamic therapy for primary cutaneous B-cell lymphoma: a pilot study. J Am Acad Dermatol. 2006;54(3):524-6.
19. Nistico S, Costanzo A, Saraceno R, Chimenti S. Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides. Br J Dermatol. 2004;151(4):877-9.
20. Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 1998;40:109-115.
21. Hoppe RT, Cox RS, Fuks Z i inni. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979;63:691-700.
22. Reddy S, Parker CM, Shidnia H, I inni. Total skin electron beam radiation therapy for mycosis fungoides. Am S Clin Oncol 1992;15:119-124.
23. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1057-76.
24. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apheresis Sci 2003;28:81-89.
25. Bunn PA, Jr., Hoffman SJ, Norris D i inni. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121:592-602.
26. Tsimberidou AM, Giles F, Duvic M I inni. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series Cancer. 2004;15;100(2):342-9.
27. Marchi E, Alinari L, Tani M I inni. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005; 1;104(11):2437-41.
28. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34(3):470-81.
29. Di Bella NJ, Khan MM, Dakhil SR, Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study. Clin Lymphoma. 2003;3(4):235-40.
30. Di Lorenzo G, Di Trolio R, Delfino M, De Placido S. Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol. 2005;153(1):183-5.
31. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 1995;9:1109-1116.
32. Jumbou O, N'Guyen JM, Tessier MH I inni. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 1999;140:427-31.
33. Bunn PA, Jr., Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986;57(suppl):1689-1695.
34. Olsen EA, Rosen ST, Vollmer RT i inni. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20:395-407.
35. Vonderheid EC, Bigler RD, Greenberg AS I inni. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J Clin Oncol 1994;17:255-263.
36. Foss FM, Ihde DC, Breneman DL i inni. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 1992;10:1907-1913.
37. Foss FM, Ihde DC, Linnoila IR I inni. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 1994;12:2051-2059.
38. Chiarion-Sileni V, Bononi A, Fornasa CV I inni. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer. 2002, 1;95(3):569-75.
39. Kessler JF, Jones SE, Levine N, i inni. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1987;123(2):201-4.
40. Foss FM. Cutaneous T-cell lymphoma. Haematology (Am Soc Haematol Educ Prog) 2002;273-282.
41. Vittorio CC, Junkins-Hopkins JM, McGinnis KS I inni. New biologic agents for the treatment of cutaneous T-cell lymphoma. Recent Results Cancer Res 2002;160:321-8.
42. Duvic M, Hymes K, Heald P I inni. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
43. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.
44. Michaelis S, Cozzio A, Kempf WI inni. Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides. Dermatology. 2004;209(1):72-4.
45. McGinnis KS, Junkins-Hopkins JM, Crawford G i inni. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol. 2004;50(3):375-9.
46. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88.
47. Lundin J, Hagberg H, Repp R. I inni. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-4272.
48. Gellrich S, Muche JM, Wilks A i inni. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation Br J Dermatol. 2005;153(1):167-73.